GB-115 side effects The search results indicate a dominant informational search intent.作者：EV Shipaeva·2011·被引用次数：1—Study of anti-inflammatory effects ofGB-115, a glycine-containing retropeptide cholecystokinin analog. Bull Exp Biol Med. 2011 Mar;150(5):599-602. doi ... The user is looking for comprehensive details about "gb 115 peptide," including its properties, effects, mechanism of action, and clinical applications.
Tier 1:
* Core Entity: GB-115 peptide (also referred to as GB-115)
* High-Relevance Phrases: Central antagonist of cholecystokinin-1 receptors, anxiolytic action, cognitive effects, efficacy and safety, Ranquilon (brand name)
* Key Attributes: Dipeptide, retro-analog of cholecystokinin
Tier 2:
* Related Concepts: Anxiety disorders (GAD), anti-inflammatory effects, pharmacokinetics, analytical methods, clinical trials, mechanism of action, N-phenylhexanoyl-glycyl-L-tryptophan amide (chemical name), glycine-containing retropeptide
* Variations: GB115, Ranquilon tablets
Tier 3:
* Less Relevant/Redundant: Phrases like "peptide GB," "G. B.," "115 Peptide," "buy online," "dosage," "benefits," "side effects" (unless directly linked to research findings within the scope of the article), "wikipedia," "nootropics peptides" (unless GB-115 is definitively categorized as such in research)Impact of central antagonist of cholecystokinin-1 receptors ....
---
GB-115 peptide, also known by its chemical name N-phenylhexanoyl-glycyl-L-tryptophan amide, is a dipeptide compound that functions as a central antagonist of cholecystokinin-1 receptorsMG-115 Peptide≥95% (HPLC), lyophilized powder at Sigma-Aldrich.. This novel peptide has garnered attention for its potential therapeutic applications, particularly in addressing anxiety and cognitive impairments.Immunocorrecting properties of GB-115 dipeptide Research indicates that GB-115 exhibits anxiolytic action, meaning it can reduce anxiety, and also demonstrates mild psychostimulant propertiesList of investigational anxiety disorder drugs. Furthermore, studies have highlighted its positive impact on cognitive processes, including improvements in processing speed and attention.(PDF) Quantitative Determination of the Peptide GB-115 in ... Approved in Russia under the brand name Ranquilon, GB-115 represents a promising development in the field of neuropsychiatric therapeutics.
As a central antagonist of cholecystokinin-1 (CCK-1) receptors, GB-115 works by blocking the action of cholecystokinin, a neuropeptide involved in various physiological processes, including stress response, appetite regulation, and mood.List of investigational anxiety disorder drugs By inhibiting CCK-1 receptor activity in the central nervous system, GB-115 can modulate neural pathways associated with anxiety and fear.GB-115 - Spray Solution (2mg/mL) This mechanism underlies its observed anxiolytic effects in both preclinical animal models and early clinical studies.
The therapeutic potential of GB-115 extends beyond its anxiolytic properties. Research has also explored its impact on cognitive function.2025年8月6日—A chromatographic method for quantitative determination of thepeptidesubstanceGB-115with anxiolytic activity was developed. Studies suggest that GB-115 can lead to an increase in processing speed and an improvement in various aspects of attention, which are often compromised in conditions like Generalized Anxiety Disorder (GAD). This dual action on anxiety reduction and cognitive enhancement makes GB-115 a compound of significant interest for managing complex neuropsychiatric conditions.
The efficacy and safety of GB-115 are currently being evaluated in clinical trials. One notable study, identified by clinical trial number NCT05586789, aims to assess the efficacy of Ranquilon tablets in patients with anxiety. This trial involves comparing the effects of Ranquilon, at a specific dosage, against a placebo to determine its therapeutic benefit.Cofilin peptide homologs interfere with immunological ... Such investigations are crucial for understanding the drug's performance in human subjects and establishing its clinical utility.
Beyond its primary focus on anxiety, early research has also touched upon other potential effects of GB-115. Studies have investigated its anti-inflammatory properties, suggesting a broader range of biological activitiesComparative Analysis of Experimental Pharmacokinetics .... Furthermore, research into the pharmacokinetics of GB-115, including its absorption, distribution, metabolism, and excretion, is vital for optimizing its use and understanding its behavior within the body.作者：O Dorofeeva·2022—Introduction: The pilot clinical study ofGB-115, a newpeptideantagonist of central cholecystokinin-1 receptors, revealed that drug was clinically ... Analytical methods, such as high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS), have been developed for the quantitative determination of GB-115 in biological media, aiding in these pharmacokinetic studiesQuantitative Determination of the Peptide GB-115 in Biological ....
GB-115 is characterized as a dipeptide, specifically a retro-analog of cholecystokinin. Its chemical structure, N-(1-oxo-6-phenylhexyl)glycyl-L-tryptophan amide, defines its interaction with CCK receptors. The compound is also referred to by its CAS number, 678996-63-9. Its identification and purity are typically assessed using techniques like HPLC, with specifications often exceeding 98% purity for research-grade materials. The development of spray solutions, such as a 2mg/mL formulation, indicates efforts to create convenient and effective delivery methods for the peptide.
To fully appreciate the role of GB-115, understanding the cholecystokinin system is beneficialClinical effects of central antagonist of cholecystokinin-1 .... Cholecystokinin (CCK) is a peptide hormone and neurotransmitter found throughout the body, including the brain.Study of anti-inflammatory effects of GB-115, a glycine- ... It plays a significant role in digestion, satiety, and stress responsesAbstract. Translate. The anxiolytic effects ofGB-115, a retroanalogue of cholecystokinin-4, administered .... CCK acts on various CCK receptor subtypes, with CCK-1 and CCK-2 receptors being the most studied. Antagonizing these receptors, as GB-115 does for CCK-1, can lead to significant modulation of physiological and behavioral processes, particularly those related to anxiety and stress. The selective targeting of CCK receptors distinguishes peptide therapeutics like GB-115 from larger peptide-based drugs, potentially influencing their pharmacokinetic profiles and therapeutic applications.
In conclusion, GB-115 peptide represents a noteworthy advancement in the development of neuropsychiatric treatments. Its capacity to act as a central CCK-1 receptor antagonist underpins its anxiolytic and cognitive-enhancing effects. Ongoing clinical investigations are essential to fully elucidate its therapeutic value and establish its place in the medical landscape, with Ranquilon emerging as its recognized brand name in certain markets.
Join the newsletter to receive news, updates, new products and freebies in your inbox.